Implications of MMP9 for blood brain barrier disruption and hemorrhagic transformation following ischemic stroke

Frontiers in Cellular Neuroscience

Volumn 10, Issue MAR2016, 2016, Pages

  Turner, Renée J ^a   Sharp, Frank R ^b  

^a UNIVERSITY OF ADELAIDE   (Australia)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Blood brain barrier; Cerebral edema; Hemorrhagic transformation; Ischemic stroke; MMP 9; Neutrophils; TPA

Indexed keywords

ALTEPLASE; GELATINASE A; GELATINASE B; ILOMASTAT; REACTIVE OXYGEN METABOLITE; STROMELYSIN; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE PLASMINOGEN ACTIVATOR; TUMOR NECROSIS FACTOR ALPHA;

AUTOPSY; BLOOD BRAIN BARRIER; BLOOD CLOT LYSIS; BRAIN EDEMA; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CELL MIGRATION; COMPARATIVE STUDY; ENZYME INHIBITION; GENE INACTIVATION; HUMAN; INFARCT VOLUME; NATIONAL INSTITUTES OF HEALTH STROKE SCALE; NERVOUS SYSTEM PARAMETERS; NEUTROPHIL; NONHUMAN; OXIDATIVE STRESS; PROTEIN EXPRESSION; REVIEW;

EID: 84961751138     PISSN: 16625102     EISSN: None     Source Type: Journal    
DOI: 10.3389/fncel.2016.00056     Document Type: Review

References (132)

1. Adibhatla, R. M. and Hatcher, J. F. (2008). Tissue plasminogen activator (tPA) and matrix metalloproteinases in the pathogenesis of stroke: therapeutic strategies. CNS Neurol. Disord. Drug Targets 7, 243-253. doi: 10.2174/187152708784936608
2. Agrawal, S. M. Lau, L. and Yong, V. W. (2008). MMPs in the central nervous system: where the good guys go bad. Semin. Cell Dev. Biol. 19, 42-51. doi: 10.1016/j.semcdb.2007.06.003
3. Alcaide, P. Auerbach, S. and Luscinskas, F. W. (2009). Neutrophil recruitment under shear flow: it's all about endothelial cell rings and gaps. Microcirculation 16, 43-57. doi: 10.1080/10739680802273892
4. Amantea, D. Certo, M. Russo, R. Bagetta, G. Corasaniti, M. T. and Tassorelli, C. (2014). Early reperfusion injury is associated to MMP2 and IL-1beta elevation in cortical neurons of rats subjected to middle cerebral artery occlusion. Neuroscience 277, 755-763. doi: 10.1016/j.neuroscience.2014.07.064
5. Amantea, D. Corasaniti, M. T. Mercuri, N. B. Bernardi, G. and Bagetta, G. (2008). Brain regional and cellular localization of gelatinase activity in rat that have undergone transient middle cerebral artery occlusion. Neuroscience 152, 8-17. doi: 10.1016/j.neuroscience.2007.12.030
6. Anthony, D. C. Ferguson, B. Matyzak, M. K. Miller, K. M. Esiri, M. M. and Perry, V. H. (1997). Differential matrix metalloproteinase expression in cases ofmultiple sclerosis and stroke. Neuropathol. Appl. Neurobiol. 23, 406-415. doi: 10.1111/j.1365-2990.1997.tb01315.x
7. Asahi, M. Asahi, K. Wang, X. and Lo, E. H. (2000). Reduction of tissue plasminogen activator-induced hemorrhage and brain injury by free radical spin trapping after embolic focal cerebral ischemia in rats. J. Cereb. Blood Flow Metab. 20, 452-457. doi: 10.1097/00004647-200003000-00002
8. Asahi, M. Sumii, T. Fini, M. E. Itohara, S. and Lo, E. H. (2001a). Matrix metalloproteinase 2 gene knockout has no effect on acute brain injury after focal ischemia. Neuroreport 12, 3003-3007. doi: 10.1097/00001756-20010917000050
9. Asahi, M. Wang, X. Mori, T. Sumii, T. Jung, J. C. Moskowitz, M. A. et al. (2001b). Effects of matrix metalloproteinase-9 gene knock-out on the proteolysis of blood-brain barrier and white matter components after cerebral ischemia. J. Neurosci. 21, 7724-7732.
10. Bajor, M. and Kaczmarek, L. (2013). Proteolytic remodeling of the synaptic cell adhesion molecules (CAMs) by metzincins in synaptic plasticity. Neurochem. Res. 38, 1113-1121. doi: 10.1007/s11064-012-0919-6
11. Bakowski, B. and Tschesche, H. (1992). Migration of polymorphonuclear leukocytes through human amnion membrane-a scanning electron microscopic study. Biol. Chem. Hoppe Seyler 373, 529-546.
12. Bauer, A. T. Bürgers, H. F. Rabie, T. and Marti, H. H. (2010). Matrix metalloproteinase-9 mediates hypoxia-induced vascular leakage in the brain via tight junction rearrangement. J. Cereb. Blood Flow Metab. 30, 837-848. doi: 10.1038/jcbfm.2009.248
13. Benarroch, E. E. (2007). Tissue plasminogen activator: beyond thrombolysis. Neurology 69, 799-802. doi: 10.1212/01.wnl.0000269668.08747.78
14. Burk, J. Burggraf, D. Vosko, M. Dichgans, M. and Hamann, G. F. (2008). Protection of cerebral microvasculature after moderate hypothermia following experimental focal cerebral ischemia in mice. Brain Res. 1226, 248-255. doi: 10.1016/j.brainres.2008.06.015
15. Candelario-Jalil, E. Yang, Y. and Rosenberg, G. A. (2009). Diverse roles of matrix metalloproteinases and tissue inhibitors of metalloproteinases in neuroinflammation and cerebral ischemia. Neuroscience 158, 983-994. doi: 10.1016/j.neuroscience.2008.06.025
16. Carbone, F. Vuilleumier, N. Bertolotto, M. Burger, F. Galan, K. Roversi, G. et al. (2015). Treatment with recombinant tissue plasminogen activator (r-TPA) induces neutrophil degranulation in vitro via defined pathways. Vascul Pharmacol. 64, 16-27. doi: 10.1016/j.vph.2014.11.007
17. Castellanos, M. Leira, R. Serena, J. Pumar, J. M. Lizasoain, I. Castillo, J. et al. (2003). Plasma metalloproteinase-9 concentration predicts hemorrhagic transformation in acute ischemic stroke. Stroke 34, 40-46. doi: 10.1161/01.STR.0000046764.57344.31
18. Castellanos, M. Sobrino, T. Millán, M. García, M. Arenillas, J. Nombela, F. et al. (2007). Serum cellular fibronectin and matrix metalloproteinase-9 as screening biomarkers for the prediction of parenchymal hematoma after thrombolytic therapy in acute ischemic stroke: a multicenter confirmatory study. Stroke 38, 1855-1859. doi: 10.1161/STROKEAHA.106.481556
19. Chang, D. I. Hosomi, N. Lucero, J. Heo, J. H. Abumiya, T. Mazar, A. P. et al. (2003). Activation systems for latent matrix metalloproteinase-2 are upregulated immediately after focal cerebral ischemia. J. Cereb. Blood Flow Metab. 23, 1408-1419. doi: 10.1097/01.WCB.0000091765.61714.30
20. Chesler, L. Golde, D. W. Bersch, N. and Johnson, M. D. (1995). Metalloproteinase inhibition and erythroid potentiation are independent activities of tissue inhibitorofmetalloproteinases-1. Blood 86, 4506-4515.
21. Choi, E. Y. Santoso, S. and Chavakis, T. (2009). Mechanisms of neutrophil transendothelial migration. Front. Biosci. 14, 1596-1605. doi: 10.2741/3327
22. Clark, A. W. Krekoski, C. A. Bou, S. S. Chapman, K. R. and Edwards, D. R. (1997). Increased gelatinase A (MMP-2) and gelatinase B (MMP-9) activities in human brain after focal ischemia. Neurosci. Lett. 238, 53-56. doi: 10.1016/S0304-3940(97)00859-8
23. Clark, I. M. Swingler, T. E. Sampieri, C. L. and Edwards, D. R. (2008). The regulation of matrix metalloproteinases and their inhibitors. Int. J. Biochem. Cell Biol. 40, 1362-1378. doi: 10.1016/j.biocel.2007.12.006
24. Conant, K. Allen, M. and Lim, S. T. (2015). Activity dependent CAM cleavage and neurotransmission. Front. Cell. Neurosci. 9:305. doi: 10.3389/fncel.2015.00305
25. Copin, J. C. Goodyear, M. C. Gidday, J. M. Shah, A. R. Gascon, E. Dayer, A. et al. (2005). Role of matrix metalloproteinases in apoptosis after transient focal cerebral ischemia in rats and mice. Eur. J. Neurosci. 22, 1597-1608. doi: 10.1111/j.1460-9568.2005.04367.x
26. Cuadrado, E. Ortega, L. Hernández-Guillamon, M. Penalba, A. Fernández-Cadenas, I. Rosell, A. et al. (2008). Tissue plasminogen activator (t-PA) promotes neutrophil degranulation and MMP-9 release. J. Leukoc. Biol. 84, 207-214. doi: 10.1189/jlb.0907606
27. Cuadrado, E. Rosell, A. Borrell-Pagès, M. García-Bonilla, L. Hernández-Guillamon, M. Ortega-Aznar, A. et al. (2009). Matrix metalloproteinase-13 is activated and is found in the nucleus of neural cells after cerebral ischemia. J. Cereb. Blood Flow Me tab. 29, 398-410. doi: 10.1038/jcbfm.2008.130
28. Cunningham, L. A. Wetzel, M. and Rosenberg, G. A. (2005). Multiple roles for MMPs and TIMPs in cerebral ischemia. Glia 50, 329-339. doi: 10.1002/glia.20169
29. Dejonckheere, E. Vandenbroucke, R. E. and Libert, C. (2011). Matrix metalloproteinases as drug targets in ischemia/reperfusion injury. Drug Discov. Today 16, 762-778. doi: 10.1016/j.drudis.2011.06.009
30. Fanjul-Fernández, M. Folgueras, A. R. Cabrera, S. and López-Otín, C. (2010). Matrix metalloproteinases: evolution, gene regulation and functional analysis in mouse models. Biochim. Biophys. Acta 1803, 3-19. doi: 10.1016/j.bbamcr.2009.07.004
31. Fernandez-Patron, C. Zouki, C. Whittal, R. Chan, J. S. Davidge, S. T. and Filep, J. G. (2001). Matrix metalloproteinases regulate neutrophil-endothelial cell adhesion through generation of endothelin-1[1-32]. FASEB J. 15, 2230-2240. doi: 10.1096/fj.01-0178com
32. Ferry, G. Lonchampt, M. Pennel, L. de Nanteuil, G. Canet, E. and Tucker, G. C. (1997). ActivationofMMP-9 byneutrophil elastase inaninvivo modelofacute lunginjury. FEBS Lett. 402, 111-115. doi: 10.1016/S0014-5793(96)01508-6
33. Fiorelli, M. Bastianello, S. von Kummer, R. del Zoppo, G. J. Larrue, V. Lesaffre, E. et al. (1999). Hemorrhagic transformation within 36 hours of a cerebral infarct: relationships with early clinical deterioration and 3-month outcome in the European Cooperative Acute Stroke Study I (ECASS I) cohort. Strok 30, 2280-2284. doi: 10.1161/01.STR.30.11.2280
34. Fujimoto, M. Takagi, Y. Aoki, T. Hayase, M. Marumo, T. Gomi, M. etal. (2008). Tissue inhibitor of metalloproteinases protect blood-brain barrier disruption in focal cerebral ischemia. J. Cereb. Blood Flow Metab. 28, 1674-1685. doi: 10.1038/jcbfm.2008.59
35. Fujimura, M. Gasche, Y. Morita-Fujimura, Y. Massengale, J. Kawase, M. and Chan, P. H. (1999). Early appearance of activated matrix metalloproteinase-9 and blood-brain barrier disruption in mice after focal cerebral ischemia and reperfusion. Brain Res. 842, 92-100. doi: 10.1016/S0006-8993(99)01843-0
36. Fujimura, M. Watanabe, M. Narisawa, A. Shimizu, H. and Tominaga, T. (2009). Increased expression of serum Matrix Metalloproteinase-9 in patients with moyamoya disease. Surg. Neurol. 72, 476-480. doi: 10.1016/j.surneu.2008.10.009
37. Gasche, Y. Copin, J. C. Sugawara, T. Fujimura, M. and Chan, P. H. (2001). Matrix metalloproteinase inhibition prevents oxidative stress-associated blood-brain barrier disruption after transient focal cerebral ischemia. J. Cereb. Blood Flow Metab. 21, 1393-1400. doi: 10.1097/00004647-200112000-00003
38. Gasche, Y. Fujimura, M. Morita-Fujimura, Y. Copin, J. C. Kawase, M. Massengale, J. et al. (1999). Early appearance of activated matrix metalloproteinase-9 after focal cerebral ischemia in mice: a possible role in blood-brain barrier dysfunction. J. Cereb. Blood Flow Metab. 19, 1020-1028. doi: 10.1097/00004647-199909000-00010
39. Gasche, Y. Soccal, P. M. Kanemitsu, M. and Copin, J. C. (2006). Matrix metalloproteinases and diseases of the central nervous system with a special emphasis on ischemic brain. Front. Biosci. 11, 1289-1301. doi: 10.2741/1883
40. Gautier, S. Ouk, T. Petrault, O. Caron, J. and Bordet, R. (2009). Neutrophils contribute to intracerebral haemorrhages after treatment with recombinant tissue plasminogen activator following cerebral ischaemia. Br. J. Pharmacol. 156, 673-679. doi: 10.1111/j.1476-5381.2009.00068.x
41. Gidday, J. M. Gasche, Y. G. Copin, J. C. Shah, A. R. Perez, R. S. Shapiro, S. D. et al. (2005). Leukocyte-derived matrix metalloproteinase-9 mediates blood-brain barrier breakdown and is proinflammatory after transient focal cerebral ischemia. Am. J. Physiol. Heart Circ. Physiol. 289, H558-H568. doi: 10.1152/ajpheart.01275.2004
42. Golab, P. Boguszewska-Czubara, A. Kielbus, M. and Kurzepa, J. (2014). The rtPA increases MMP-9 activityin serumduringischaemic stroke. Neurol. Neurochir. Pol. 48, 309-314. doi: 10.1016/j.pjnns.2014.07.012
43. Gu, Z. Kaul, M. Yan, B. Kridel, S. J. Cui, J. Strongin, A. et al. (2002). Snitrosylation of matrix metalloproteinases: signaling pathway to neuronal cell death. Science 297, 1186-1190. doi: 10.1126/science.1073634
44. Gurney, K. J. Estrada, E. Y. and Rosenberg, G. A. (2006). Blood-brain barrier disruption by stromelysin-1 facilitates neutrophil infiltration in neuroinflammation. Neurobiol. Dis. 23, 87-96. doi: 10.1016/j.nbd.2006.02.006
45. Gürsoy-Ozdemir, Y. Bolay, H. Saribas, O. and Dalkara, T. (2000). Role of endothelial nitric oxide generation and peroxynitrite formation in reperfusion injury after focal cerebral ischemia. Stroke 31, 1974-1980. doi: 10.1161/01.STR.31.8.1974
46. Hacke, W. Schwab, S. Horn, M. Spranger, M. De Georgia, M. and von Kummer, R. (1996). 'Malignant' middle cerebral artery territory infarction: clinical course and prognostic signs. Arch. Neurol. 53, 309-315. doi: 10.1001/archneur.1996.00550040037012
47. Harris, A. K. Ergul, A. Kozak, A. Machado, L. S. Johnson, M. H. and Fagan, S. C. (2005). Effect of neutrophil depletion on gelatinase expression, edema formation and hemorrhagic transformation after focal ischemic stroke. BMC Neurosci. 6:49. doi: 10.1186/1471-2202-6-49
48. Heo, J. H. Kim, S. H. Lee, K. Y. Kim, E. H. Chu, C. K. and Nam, J. M. (2003). Increase in plasma matrix metalloproteinase-9 in acute stroke patients with thrombolysis failure. Stroken 34, e48-e50. doi: 10.1161/01.str.0000073788.81170.1c
49. Heo, J. H. Lucero, J. Abumiya, T. Koziol, J. A. Copeland, B. R. and del Zoppo, G. J. (1999). Matrix metalloproteinases increase very early during experimental focal cerebral ischemia. J. Cereb. Blood Flow Metab. 19, 624-633. doi: 10.1097/00004647-199906000-00005
50. Horstmann, S. Kalb, P. Koziol, J. Gardner, H. and Wagner, S. (2003). Profiles of matrix metalloproteinases, their inhibitors, and laminin in stroke patients: influence of different therapies. Stroken 34, 2165-2170. doi: 10.1161/01.STR.0000088062.86084.F2
51. Hu, Q. Chen, C. Yan, J. Yang, X. Shi, X. Zhao, J. et al. (2009). Therapeutic application of gene silencing MMP-9 in a middle cerebral artery occlusion-induced focal ischemia rat model. Exp. Neurol. 216, 35-46. doi: 10.1016/j.expneurol.2008.11.007
52. Inzitari, D. Giusti, B. Nencini, P. Gori, A. M. Nesi, M. Palumbo, V. et al. (2013). MMP9 variation after thrombolysis is associated with hemorrhagic transformation of lesion and death. Stroke 44, 2901-2903. doi: 10.1161/STROKEAHA.113.002274
53. Jickling, G. C. Liu, D. Stamova, B. Ander, B. P. Zhan, X. Lu, A. et al. (2014). Hemorrhagic transformation after ischemic stroke in animals and humans. J. Cereb. Blood FlowMetab. 34, 185-199. doi: 10.1038/jcbfm.2013.203
54. Justicia, C. Panés, J. Solé, S. Cervera, A. Deulofeu, R. Chamorro, A. et al. (2003). Neutrophil infiltration increases matrix metalloproteinase-9 in the ischemic brain after occlusion/reperfusion of the middle cerebral artery in rats. J. Cereb. Blood Flow Metab. 23, 1430-1440. doi: 10.1097/01.WCB.0000090680.07515.C8
55. Keck, T. Balcom, J. H. IV, Fernández-del Castillo, C. Antoniu, B. A. and Warshaw, A. L. (2002). Matrix metalloproteinase-9 promotes neutrophil migration and alveolar capillary leakage in pancreatitis-associated lung injury in the rat. Gastroenterology 122, 188-201. doi: 10.1053/gast.2002.30348
56. Kelly, M. A. Shuaib, A. and Todd, K. G. (2006). Matrix metalloproteinase activation and blood-brain barrier breakdown following thrombolysis. Exp. Neurol. 200, 38-49. doi: 10.1016/j.expneurol.2006.01.032
57. Khandoga, A. Kessler, J. S. Hanschen, M. Khandoga, A. G. Burggraf, D. Reichel, C. et al. (2006). Matrix metalloproteinase-9 promotes neutrophil and T cell recruitment and migration in the postischemic liver. J. Leukoc. Biol. 79, 1295-1305. doi: 10.1189/jlb.0805468
58. Kim, Y. S. Kim, S. S. Cho, J. J. Choi, D. H. Hwang, O. Shin, D. H. et al. (2005). Matrix metalloproteinase-3: a novel signaling proteinase from apoptotic neuronal cells that activates microglia. J. Neurosci. 25, 3701-3711. doi: 10.1523/JNEUROSCI.4346-04.2005
59. Kuroiwa, T. Cahn, R. Juhler, M. Goping, G. Campbell, G. and Klatzo, I. (1985). Role of extracellular proteins in the dynamics of vasogenic brain edema. Acta Neuropathol. 66, 3-11. doi: 10.1007/BF00698288
60. Kurzepa, J. Szczepanska-Szerej, A. Stryjecka-Zimmer, M. Malecka-Massalska, T. and Stelmasiak, Z. (2006). Simvastatin could prevent increase of the serum MMP-9/TIMP-1 ratio in acute ischaemic stroke. Folia Biol. 52, 181-183.
61. Lapchak, P. A. Chapman, D. F. and Zivin, J. A. (2000). Metalloproteinase inhibition reduces thrombolytic (tissue plasminogen activator)-induced hemorrhage after thromboembolic stroke. Stroke 31, 3034-3040. doi: 10.1161/01.STR.31.12.3034
62. Lee, K. S. Jin, S. M. Kim, H. J. and Lee, Y. C. (2003). Matrix metalloproteinase inhibitor regulates inflammatory cell migration by reducing ICAM-1 and VCAM-1 expression in a murine model of toluene diisocyanate-induced asthma. J. AllergyClin. Immunol. 111, 1278-1284. doi: 10.1067/mai.2003.1501
63. Lenglet, S. Montecucco, F. and Mach, F. (2015). Role ofmatrixmetalloproteinases in animal models of ischemic stroke. Curr. Vasc. Pharmacol. 13, 161-166. doi: 10.2174/15701611113116660161
64. Lenglet, S. Montecucco, F. Mach, F. Schaller, K. Gasche, Y. and Copin, J. C. (2014). Analysis of the expression of nine secreted matrix metalloproteinases and their endogenous inhibitors in the brain of mice subjected to ischaemic stroke. Thromb. Haemost. 112, 363-378. doi: 10.1160/TH14-01-0007
65. Li, D. D. Song, J. N. Huang, H. Guo, X. Y. An, J. Y. Zhang, M. et al. (2013). The roles of MMP-9/TIMP-1 in cerebral edema following experimental acute cerebral infarction in rats. Neurosci. Lett. 550, 168-172. doi: 10.1016/j.neulet.2013.06.034
66. Lucivero, V. Prontera, M. Mezzapesa, D. M. Petruzzellis, M. Sancilio, M. Tinelli, A. et al. (2007). Different roles of matrix metalloproteinases-2 and -9 after human ischaemic stroke. Neurol. Sci. 28, 165-170. doi: 10.1007/s10072-007-0814-0
67. Lukes, A. Mun-Bryce, S. Lukes, M. and Rosenberg, G. A. (1999). Extracellular matrix degradation bymetalloproteinases and central nervous system diseases. Mol. Neurobiol. 19, 267-284. doi: 10.1007/BF02821717
68. Lynch, J. R. Blessing, R. White, W. D. Grocott, H. P. Newman, M. F. and Laskowitz, D. T. (2004). Novel diagnostic test for acute stroke. Stroke 35, 57-63. doi: 10.1161/01.STR.0000105927.62344.4C
69. Machado, L. S. Sazonova, I. Y. Kozak, A. Wiley, D. C. El-Remessy, A. B. Ergul, A. et al. (2009). Minocycline and tissue-type plasminogen activator for stroke: assessment of interaction potential. Stroke 40, 3028-3033. doi: 10.1161/STROKEAHA.109.556852
70. Maier, C. M. Hsieh, L. Yu, F. Bracci, P. and Chan, P. H. (2004). Matrix metalloproteinase-9 and myeloperoxidase expression: quantitative analysis by antigen immunohistochemistryin a model oftransientfocal cerebral ischemia. Stroke 35, 1169-1174. doi: 10.1161/01.STR.0000125861.55804.f2
71. Manabe, S. Gu, Z. and Lipton, S. A. (2005). Activation of matrix metalloproteinase-9 via neuronal nitric oxide synthase contributes to NMDA-induced retinal ganglion cell death. Invest. Ophthalmol. Vis. Sci. 46, 4747-4753. doi: 10.1167/iovs.05-0128
72. McCarthy, S. M. Bove, P. F. Matthews, D. E. Akaike, T. and van der Vliet, A. (2008). Nitric oxide regulation of MMP-9 activation and its relationship to modifications of the cysteine switch. Biochemistry 47, 5832-5840. doi: 10.1021/bi702496v
73. Moldes, O. Sobrino, T. Millán, M. Castellanos, M. Pérez de la Ossa, N. Leira, R. et al. (2008). High serum levels of endothelin-1 predict severe cerebral edema in patients with acute ischemic stroke treated with t-PA. Stroke 39, 2006-2010. doi: 10.1161/STROKEAHA.107.495044
74. Montaner, J. Alvarez-Sabín, J. Barberá, G. Anglés, A. Molina, C. Abilleira, S. et al. (2001a). [Correlation between the expression of proinflammatory cytokines and matrix metalloproteinases in the acute phase of an ischemic stroke]. Rev. Neurol. 33, 115-118.
75. Montaner, J. Alvarez-Sabín, J. Molina, C. Anglés, A. Abilleira, S. Arenillas, J. et al. (2001b). Matrix metalloproteinase expression after human cardioembolic stroke: temporal profile and relation to neurological impairment. Stroke 32, 1759-1766. doi: 10.1161/01.STR.32.8.1759
76. Montaner, J. Alvarez-Sabín, J. Molina, C. A. Anglés, A. Abilleira, S. Arenillas, J. et al. (2001c). Matrix metalloproteinase expression is related to hemorrhagic transformation after cardioembolic stroke. Stroke 32, 2762-2767. doi: 10.1161/hs1201.99512
77. Montaner, J. Fernández-Cadenas, I. Molina, C. A. Monasterio, J. Arenillas, J. F. Ribo, M. et al. (2003a). Safety profile of tissue plasminogen activator treatment among stroke patients carrying a common polymorphism (C-1562T) in the promoter region ofthe matrixmetalloproteinase-9 gene. Stroke 34, 2851-2855. doi: 10.1161/01.STR.0000098648.54429.1C
78. Montaner, J. Molina, C. A. Monasterio, J. Abilleira, S. Arenillas, J. F. Ribó, M. et al. (2003b). Matrix metalloproteinase-9 pretreatment level predicts intracranial hemorrhagic complications after thrombolysis in human stroke. Circulation 107, 598-603. doi: 10.1161/01.CIR.0000046451.38849.90
79. Montaner, J. Perea-Gainza, M. Delgado, P. Ribó, M. Chacón, P. Rosell, A. et al. (2008). Etiologic diagnosis of ischemic stroke subtypes with plasma biomarkers. Stroken 39, 2280-2287. doi: 10.1161/STROKEAHA.107.505354
80. Mun-Bryce, S. and Rosenberg, G. A. (1998). Matrix metalloproteinases in cerebrovascular disease. J. Cereb. Blood Flow Metab. 18, 1163-1172. doi: 10.1097/00004647-199811000-00001
81. Murata, Y. Rosell, A. Scannevin, R. H. Rhodes, K. J. Wang, X. and Lo, E. H. (2008). Extension of the thrombolytic time window with minocycline in experimental stroke. Stroke 39, 3372-3377. doi: 10.1161/STROKEAHA.108.514026
82. Nguyen, H. X. O'Barr, T. J. and Anderson, A. J. (2007). Polymorphonuclear leukocytes promote neurotoxicitythrough release ofmatrixmetalloproteinases, reactive oxygen species, and TNF-alpha. J. Neurochem. 102, 900-912. doi: 10.1111/j.1471-4159.2007.04643.x
83. Ning, M. Furie, K. L. Koroshetz, W. J. Lee, H. Barron, M. Lederer, M. et al. (2006). Association between tPA therapy and raised early matrix metalloproteinase-9 in acute stroke. Neurology 66, 1550-1555. doi: 10.1212/01.wnl.0000216133.98416.b4
84. Oda, T. Katori, M. Hatanaka, K. and Nagai, Y. (1995). Inhibition of neutrophil migration by a selective inhibitor of matrix metalloproteinase: analysis by intravital microscopy. Mediators Inflamm. 4, 133-137. doi: 10.1155/S0962935195000238
85. Opdenakker, G. Van den Steen, P. E. Dubois, B. Nelissen, I. Van Coillie, E. Masure, S. et al. (2001). Gelatinase B functions as regulator and effector in leukocyte biology. J. Leukoc. Biol. 69, 851-859.
86. Orbe, J. Barrenetxe, J. Rodriguez, J. A. Vivien, D. Orset, C. Parks, W. C. et al. (2011). Matrix metalloproteinase-10 effectively reduces infarct size in experimental stroke by enhancing fibrinolysis via a thrombin-activatable fibrinolysis inhibitor-mediated mechanism. Circulation 124, 2909-2919. doi: 10.1161/CIRCULATIONAHA.111.047100
87. Piccardi, B. Palumbo, V. Nesi, M. Nencini, P. Gori, A. M. Giusti, B. et al. (2015). Unbalanced metalloproteinase-9 and tissue inhibitors of metalloproteinases ratios predict hemorrhagic transformation oflesion in ischemic stroke patients treated with thrombolysis: results from the MAGIC study. Front. Neurol. 6:121. doi: 10.3389/fneur.2015.00121
88. Planas, A. M. Solé, S. and Justicia, C. (2001). Expression and activation ofmatrix metalloproteinase-2 and-9 in rat brain after transient focal cerebral ischemia. Neurobiol. Dis. 8, 834-846. doi: 10.1006/nbdi.2001.0435
89. Ra, H. J. and Parks, W. C. (2007). Control of matrix metalloproteinase catalytic activity. Matrix Biol. 26, 587-596. doi: 10.1016/j.matbio.2007.07.001
90. Ramos-Fernandez, M. Bellolio, M. F. and Stead, L. G. (2011). Matrix metalloproteinase-9 as a marker for acute ischemic stroke: a systematic review. J. Stroke Cerebrovasc. Dis. 20, 47-54. doi: 10.1016/j.jstrokecerebrovasdis.2009.10.008
91. Ranasinghe, H. S. Scheepens, A. Sirimanne, E. Mitchell, M. D. Williams, C. E. and Fraser, M. (2012). Inhibitionof MMP-9 activityfollowinghypoxicischemia in the developing brain using a highly specific inhibitor. Dev. Neurosci. 34, 417-427. doi: 10.1159/000343257
92. Reynolds, M. A. Kirchick, H. J. Dahlen, J. R. Anderberg, J. M. McPherson, P. H. Nakamura, K. K. et al. (2003). Early biomarkers of stroke. Clin. Chem. 49, 1733-1739. doi: 10.1373/49.10.1733
93. Rivera, S. Ogier, C. Jourquin, J. Timsit, S. Szklarczyk, A. W. Miller, K. et al. (2002). Gelatinase, B. and TIMP-1 are regulated in a cell-and time-dependent manner in association with neuronal death and glial reactivity after global forebrain ischemia. Eur. J. Neurosci. 15, 19-32. doi: 10.1046/j.0953-816x.2001.01838.x
94. Rodríguez, J. A. Sobrino, T. Orbe, J. Purroy, A. Martínez-Vila, E. Castillo, J. et al. (2013). proMetalloproteinase-10 is associated with brain damage and clinical outcome in acute ischemic stroke. J. Thromb. Haemost. 11, 1464-1473. doi: 10.1111/jth.12312
95. Rodrigues, S. F. and Granger, D. N. (2015). Blood cells and endothelial barrier function. Tissue Barriers 3:e978720. doi: 10.4161/21688370.2014.978720
96. Rodríguez-Yáñez, M. Castellanos, M. Blanco, M. García, M. M. Nombela, F. Serena, J. et al. (2006). New-onset hypertension and inflammatory response/poor outcome in acute ischemic stroke. Neurology67, 1973-1978. doi: 10.1212/01.wnl.0000247064.53130.91
97. Romanic, A. M. White, R. F. Arleth, A. J. Ohlstein, E. H. and Barone, F. C. (1998). Matrix metalloproteinase expression increases after cerebral focal ischemia in rats: inhibition of matrix metalloproteinase-9 reduces infarct size. Stroke 29, 1020-1030. doi: 10.1161/01.STR.29.5.1020
98. Rosell, A. Alvarez-Sabín, J. Arenillas, J. F. Rovira, A. Delgado, P. Fernandez-Cadenas, I. et al. (2005). A matrix metalloproteinase protein array reveals a strong relation between MMP-9 and MMP-13 with diffusion-weighted image lesion increase in human stroke. Stroke 36, 1415-1420. doi: 10.1161/01.STR.0000170641.01047.cc
99. Rosell, A. Cuadrado, E. Ortega-Aznar, A. Hernández-Guillamon, M. Lo, E. H. and Montaner, J. (2008). MMP-9-positive neutrophil infiltration is associated to blood-brain barrier breakdown and basal lamina type IV collagen degradation during hemorrhagic transformation after human ischemic stroke. Stroke 39, 1121-1126. doi: 10.1161/STROKEAHA.107.500868
100. Rosell, A. Ortega-Aznar, A. Alvarez-Sabín, J. Fernández-Cadenas, I. Ribó, M. Molina, C. A. et al. (2006). Increased brain expression of matrix metalloproteinase-9 after ischemic and hemorrhagic human stroke. Stroke 37, 1399-1406. doi: 10.1161/01.STR.0000223001.06264.af
101. Rosenberg, G. A. (2002). Matrix metalloproteinases in neuroinflammation. Glia 39, 279-291. doi: 10.1002/glia.10108
102. Rosenberg, G. A. Cunningham, L. A. Wallace, J. Alexander, S. Estrada, E. Y. Grossetete, M. et al. (2001). Immunohistochemistry of matrix metalloproteinases in reperfusion injury to rat brain: activation of MMP-9 linked to stromelysin-1 and microglia in cell cultures. Brain Res. 893, 104-112. doi: 10.1016/S0006-8993(00)03294-7
103. Rosenberg, G. A. Estrada, E. Y. and Dencoff, J. E. (1998). Matrix metalloproteinases and TIMPs are associated with blood-brain barrier opening after reperfusion in rat brain. Stroke 29, 2189-2195. doi: 10.1161/01.STR.29.10.2189
104. Rosenberg, G. A. and Yang, Y. (2007). Vasogenic edema due to tight junction disruptionbymatrixmetalloproteinases incerebral ischemia. Neurosurg. Focus 22, E4. doi: 10.3171/foc.2007.22.5.5
105. Sandoval, K. E. and Witt, K. A. (2008). Blood-brain barrier tight junction permeability and ischemic stroke. Neurobiol. Dis. 32, 200-219. doi: 10.1016/j.nbd.2008.08.005
106. Schnoor, M. and Parkos, C. A. (2008). Disassembly of endothelial and epithelial junctions during leukocyte transmigration. Front. Biosci. 13, 6638-6652. doi: 10.2741/3178
107. Shigemori, Y. Katayama, Y. Mori, T. Maeda, T. and Kawamata, T. (2006). Matrix metalloproteinase-9 is associated with blood-brain barrier opening and brain edema formation after cortical contusion in rats. Acta Neurochir. Suppl. 96, 130-133. doi: 10.1007/3-211-30714-1_29
108. Si-Tayeb, K. Monvoisin, A. Mazzocco, C. Lepreux, S. Decossas, M. Cubel, G. et al. (2006). Matrix metalloproteinase 3 is present in the cell nucleus and is involved in apoptosis. Am. J. Pathol. 169, 1390-1401. doi: 10.2353/ajpath.2006.060005
109. Sotgiu, S. Zanda, B. Marchetti, B. Fois, M. L. Arru, G. Pes, G. M. et al. (2006). Inflammatory biomarkers in blood of patients with acute brain ischemia. Eur. J. Neurol. 13, 505-513. doi: 10.1111/j.1468-1331.2006.01280.x
110. Steadman, R. St John, P. L. Evans, R. A. Thomas, G. J. Davies, M. Heck, L. W. et al. (1997). Human neutrophils do not degrade major basement membrane components during chemotactic migration. Int. J. Biochem. Cell Biol. 29, 993-1004. doi: 10.1016/S1357-2725(97)00038-1
111. Sternlicht, M. D. and Werb, Z. (2001). How matrix metalloproteinases regulate cell behavior. Annu. Rev. Cell Dev. Biol. 17, 463-516. doi: 10.1146/annurev.cellbio.17.1.463
112. Sumii, T. and Lo, E. H. (2002). Involvement of matrix metalloproteinase in thrombolysis-associated hemorrhagic transformation after embolic focal ischemia in rats. Stroke 33, 831-836. doi: 10.1161/hs0302.104542
113. Svedin, P. Hagberg, H. Sävman, K. Zhu, C. and Mallard, C. (2007). Matrix metalloproteinase-9 gene knock-out protects the immature brain after cerebral hypoxia-ischemia. J. Neurosci. 27, 1511-1518. doi: 10.1523/JNEUROSCI.4391-06.2007
114. Tan, H. K. Heywood, D. Ralph, G. S. Bienemann, A. Baker, A. H. and Uney, J. B. (2003). Tissue inhibitor ofmetalloproteinase 1 inhibits excitotoxic cell death in neurons. Mol. Cell. Neurosci. 22, 98-106. doi: 10.1016/S1044-7431(02)00024-6
115. Tang, Y. Xu, H. Du, X. Lit, L. Walker, W. Lu, A. et al. (2006). Gene expression inblood changes rapidlyinneutrophils and monocytes afterischemic stroke in humans: a microarray study. J. Cereb. Blood Flow Metab. 26, 1089-1102. doi: 10.1038/sj.jcbfm.9600264
116. Tsuji, K. Aoki, T. Tejima, E. Arai, K. Lee, S. R. Atochin, D. N. et al. (2005). Tissue plasminogen activator promotes matrix metalloproteinase-9 upregulation after focal cerebral ischemia. Stroke 36, 1954-1959. doi: 10.1161/01.STR.0000177517.01203.eb
117. Tsuruoka, A. Atsumi, C. Mizukami, H. Imai, T. Hagiwara, Y. and Hasegawa, Y. (2014). Effects of edaravone, a free radical scavenger, on circulating levels of MMP-9 and hemorrhagic transformation in patients with intravenous thrombolysis using low-dose alteplase. J. Stroke Cerebrovasc. Dis. 23, 2894-2899. doi: 10.1016/j.jstrokecerebrovasdis.2014.07.022
118. Turba, M. E. Forni, M. Gandini, G. and Gentilini, F. (2007). Recruited leukocytes and local synthesis account for increased matrix metalloproteinase-9 activity in cerebrospinal fluid of dogs with central nervous system neoplasm. J. Neurooncol. 81, 123-129. doi: 10.1007/s11060-006-9213-2
119. Van den Steen, P. E. Dubois, B. Nelissen, I. Rudd, P. M. Dwek, R. A. and Opdenakker, G. (2002). Biochemistry and molecular biology of gelatinase B or matrix metalloproteinase-9 (MMP-9). Crit. Rev. Biochem. Mol. Biol. 37, 375-536. doi: 10.1080/10409230290771546
120. Vandooren, J. Van den Steen, P. E. and Opdenakker, G. (2013). Biochemistry and molecular biology of gelatinase B or matrix metalloproteinase-9 (MMP-9): the next decade. Crit. Rev. Biochem. Mol. Biol. 48, 222-272. doi: 10.3109/10409238.2013.770819
121. Vukasovic, I. Tesija-Kuna, A. Topic, E. Supanc, V. Demarin, V. and Petrovcic, M. (2006). Matrix metalloproteinases and their inhibitors in different acute stroke subtypes. Clin. Chem. Lab. Med. 44, 428-434. doi: 10.1515/cclm.2006.079
122. Wang, C. X. Ding, X. Noor, R. Pegg, C. He, C. and Shuaib, A. (2009). Rosiglitazone alone or in combination with tissue plasminogen activator improves ischemic brain injury in an embolic model in rats. J. Cereb. Blood FlowMetab. 29, 1683-1694. doi: 10.1038/jcbfm.2009.87
123. Wang, Q. and Doerschuk, C. M. (2002). The signaling pathways induced by eutrophil-endothelial cell adhesion. Antioxid. Redox Signal. 4, 39-47. doi:10.1089/152308602753625843
124. Wang, X. Lee, S. R. Arai, K. Tsuji, K. Rebeck, G. W. and Lo, E. H. (2003). Lipoprotein receptor-mediated induction of matrix metalloproteinase by tissue plasminogen activator. Nat. Med. 9, 1313-1317. doi: 10.1038/nm926
125. Yan, C. and Boyd, D. D. (2007). Regulation of matrix metalloproteinase gene expression. J. Cell. Physiol. 211, 19-26. doi: 10.1002/jcp.20948
126. Yang, Y. Estrada, E. Y. Thompson, J. F. Liu, W. and Rosenberg, G. A. (2007). Matrix metalloproteinase-mediated disruption of tight junction proteins in cerebral vessels is reversed by synthetic matrix metalloproteinase inhibitor in focal ischemia in rat. J. Cereb. Blood Flow Metab. 27, 697-709. doi: 10.1515/CCLM.2006.079
127. Yang, Y. Jalal, F. Y. Thompson, J. F. Walker, E. J. Candelario-Jalil, E. Li, L. et al. (2011). Tissue inhibitor of metalloproteinases-3 mediates the death of immature oligodendrocytes via TNF-alpha/TACE in focal cerebral ischemia in mice. J. Neuroinflammation 8:108. doi: 10.1186/1742-2094-8-108
128. Yushchenko, M. Weber, F. Mader, M. Schöll, U. Maliszewska, M. Tumani, H. et al. (2000). Matrix metalloproteinase-9 (MMP-9) in human cerebrospinal fluid (CSF): elevated levels are primarily related to CSF cell count. J. Neuroimmunol. 110, 244-251. doi: 10.1016/S0165-5728(00)00 339-8
129. Zhao, B. Q. Tejima, E. and Lo, E. H. (2007). Neurovascular proteases in brain injury, hemorrhage and remodeling after stroke. Stroke 38, 748-752. doi: 10.1161/01.STR.0000253500.32979.d1
130. Zhao, B. Q. Wang, S. Kim, H. Y. Storrie, H. Rosen, B. R. Mooney, D. J. et al. (2006). Role of matrix metalloproteinases in delayed cortical responses after stroke. Nat. Med. 12, 441-445. doi: 10.1038/nm1387
131. Zhao, J. K. Guan, F. L. Duan, S. R. Zhao, J. W. Sun, R. H. Zhang, L. M. et al. (2013). Effect of focal mild hypothermia on expression of MMP-9, TIMP-1, Tau-1 and beta-APP in rats with cerebral ischaemia/reperfusion injury. Brain Inj. 27, 1190-1198. doi: 10.3109/02699052.2013.804206
132. Zozulya, A. Weidenfeller, C. and Galla, H. J. (2008). Pericyte-endothelial cell interaction increases MMP-9 secretion at the blood-brain barrier in vitro. Brain Res. 1189, 1-11. doi: 10.1016/j.brainres.2007.10.099